FIELD: chemistry.
SUBSTANCE: invention relates to compounds of formula (I), having histone deacetylase (HDAC) enzyme inhibiting action, stereoisomers, hydrates, solvates and pharmaceutically acceptable salts thereof, compounds of formula (II), compounds selected from a list, a method of producing compounds of formula (I), a pharmaceutical composition, an inhibition method and methods of treating using compounds of formula (I). In formulae
and
R denotes substituted or unsubstituted groups selected from (C6-C10)aryl, (C3-C12)cycloalkyl, heteroaryl, (C6-C10)aryl (C1-C6)alkyl and heterocyclyl; where the heterocyclyl hereinafter is a 5-10-member ring radical which consists of carbon atoms and 1-5 heteroatoms selected from nitrogen, oxygen and sulphur, and heteroaryl hereinafter is an aromatic heterocyclyl, and each aryl, cycloalkyl, heteroaryl, arylalkyl and heterocyclyl can be substituted with one or more substitutes selected from halogens, including fluorine, chlorine, bromine, iodine, (C1-C6)alkyl, (C1-C6)alkoxy, (C6-C10)aryl, halogen(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxy, -O-(C3-C12)cycloalkyl, -O-CH2-(C3-C12)cycloalkyl, hydroxyl, NRaRb and ORa, where Ra and Rb independently denote (C1-C6)alkyl and aryl; R1 denotes (C6-C10)aryl; R2 and R3 independently denote hydrogen, (C1-C6)alkyl, -COOR5, -CONR5R6, -CH2NR5R6, -CH2CH2NR5R6, -CH2CH2OH or -CH2OH; provided that one of R5 or R6 is hydrogen or unsubstituted alkyl, the other is neither hydrogen nor unsubstituted alkyl; R5 and R6 independently denote hydrogen, (C1-C6)alkyl, (C3-C12)cycloalkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, heteroaryl or heteroaryl(C1-C6)alkyl, which can be unsubstituted or substituted; or R5 and R6 can be combined to form a saturated or unsaturated 3-8-member ring having 0-2 heteroatoms, including N, O or S; where the heteroaryl hereinafter is a 5-10-member ring radical consisting of carbon atoms and 1-5 heteroatoms selected from nitrogen, oxygen and sulphur, and each alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl can be substituted with one or more substitutes selected from halogen, including chlorine, fluorine, bromine or iodine,(C1-C6)alkoxy and NRaRb; R4 denotes OH, (C6-C10)aryl, ortho-substituted aniline or amino (C6-C10) aryl, which can be optionally substituted with one or more groups selected from halogens, including fluorine, chlorine, bromine, iodine, hydroxyl, amino groups or (C6-C10)aryl; X denotes -NR7-, -CONR7- or -N R7CO; R7 denotes hydrogen or (C1-C6)alkyl; Y denotes (C6-C10)aryl or (C6-C10)aryl(C2-C6)alkenyl; m is an integer from 0 to 1; n is an integer from 0 to 1; o is an integer from 0 to 7; and p is an integer from 0 to 1.
EFFECT: improved method.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR OBTAINING AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE INHIBITOR OF KINASE JAK1 AND APPLICATION THEREOF | 2015 |
|
RU2671195C2 |
| METHOD OF OBTAINING HYDROXAMIC ACIDS, DERIVATIVES OF 2-ARYL-2.3-DIHYDROQUINAZOLIN-4(1H)-ONES | 2020 |
|
RU2744750C1 |
| PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2013 |
|
RU2623221C2 |
| METHOD FOR OBTAINING DISPYROINDOLINONES BASED ON 5-INDOLIDENE-2-THIOHIDANTOINES | 2020 |
|
RU2756463C1 |
| THIENO[3,2-d]PYRIMIDINE DERIVATIVES, POSSESSING INHIBITING ACTION WITH RESPECT TO PROTEINKINASE | 2011 |
|
RU2524210C2 |
| METHOD OF PRODUCING 3-AMINO-8-HYDROXY-1,6-DIOXO-2,7-DIAZASPIRO[4,4]NON-3-ENE-4-CARBONITRILES | 2012 |
|
RU2495040C1 |
| NEW HYDROXAMIC ACID DERIVATIVE | 2011 |
|
RU2575129C2 |
| METHOD OF PRODUCING 2-[(ALKYL(PHENYL)SULFANYL)METHYL]BENZAMIDES | 2022 |
|
RU2788745C1 |
| 2-THIO SUBSTITUTED DERIVATIVES OF IMIDAZOLE AND THEIR USE IN PHARMACEUTICALS | 2003 |
|
RU2331638C2 |
| NEW PHOSPHORAMIDATE NUCLEOSIDE DERIVATIVES AND APPLICATION THEREOF | 2014 |
|
RU2621709C2 |
